MyFinsight
Home
Blog
About
Ultragenyx Pharmaceutical Inc. (RARE)
Ultragenyx Pharmaceutical Inc. (RARE)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Balance Sheets Overview
Current Ratio
172.65%
Quick Ratio
155.84%
Cash Ratio
35.61%
Debt to Asset Ratio
122.47%
Unit: Thousand (K) dollars
Assets Breakdown
Total current assets
Property, plant, and equipment, ...
Intangible assets, net
Others
Liabilities Breakdown
Accumulated deficit
Additional paid-in capital
Liabilities for sales of future ...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
125,000
175,000
421,000
202,510
Marketable securities
167,000
238,000
259,000
222,738
Accounts receivable, net
200,000
121,000
158,000
112,543
Inventory
59,000
55,000
52,000
52,200
Prepaid expenses and other assets
55,000
68,000
61,000
53,215
Total current assets
606,000
657,000
951,000
643,206
Property, plant and equipment, gross
-
-
380,000
-
Less accumulated depreciation
-
-
136,000
-
Property, plant, and equipment, net
235,000
239,000
244,000
249,961
Marketable securities
144,000
121,000
57,000
22,067
Intangible assets, net
172,000
174,000
176,000
172,943
Goodwill
44,000
44,000
44,000
44,406
Other assets
63,000
61,000
60,000
57,862
Total assets
1,264,000
1,296,000
1,532,000
1,190,445
Accounts payable
39,000
42,000
31,000
40,573
Accrued liabilities
221,000
194,000
265,000
220,526
Lease liabilities
-
-
12,000
12,142
Liabilities for sales of future royalties
76,000
72,000
69,000
65,545
Other liabilities
15,000
17,000
7,000
1,236
Total current liabilities
351,000
325,000
384,000
340,022
Lease liabilities
-
-
24,000
21,691
Deferred tax liabilities
30,000
30,000
30,000
30,058
Liabilities for sales of future royalties
1,126,000
1,128,000
1,147,000
763,735
Other liabilities
41,000
42,000
20,000
18,780
Total liabilities
1,548,000
1,525,000
1,605,000
1,174,286
Noncontrolling interest
7,000
7,000
7,000
7,000
Common stock, par value of 0.001 per share - 250,000,000 shares authorizedoutstanding - 96,442,027 in 2025 and 92,484,330 in 2024
-
-
-
96
Treasury stock, at cost, 0.3 shares in 2026 and 0.2 shares in 2025
10,000
10,000
8,000
7,991
Deferred compensation obligation
10,000
10,000
8,000
7,991
Additional paid-in capital
4,518,000
4,481,000
4,451,000
4,411,531
Accumulated other comprehensive loss
0
0
1,000
820
Accumulated deficit
-4,809,000
-4,717,000
-4,532,000
-4,403,288
Total stockholders' deficit
-291,000
-236,000
-80,000
9,159
Total liabilities, noncontrolling interest and stockholders' deficit
1,264,000
1,296,000
1,532,000
1,190,445
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Balance Sheets
Accounts receivable, net
$200,000K
(60.69%↑ Y/Y)
Marketable securities
$167,000K
(-46.35%↓ Y/Y)
Cash and cash
equivalents
$125,000K
(-29.10%↓ Y/Y)
Inventory
$59,000K
(26.89%↑ Y/Y)
Prepaid expenses and
other assets
$55,000K
(-10.19%↓ Y/Y)
Total current assets
$606,000K
(-15.81%↓ Y/Y)
Property, plant, and
equipment, net
$235,000K
(-8.12%↓ Y/Y)
Intangible assets, net
$172,000K
(-1.56%↓ Y/Y)
Marketable securities
$144,000K
(179.86%↑ Y/Y)
Other assets
$63,000K
(4.79%↑ Y/Y)
Goodwill
$44,000K
(-0.91%↓ Y/Y)
Total assets
$1,264,000K
(-3.24%↓ Y/Y)
Accumulated deficit
-$4,809,000K
(-13.88%↓ Y/Y)
Treasury stock, at cost,
0.3 shares in 2026...
$10,000K
(25.14%↑ Y/Y)
Total liabilities,
noncontrolling interest and...
$1,264,000K
(-3.24%↓ Y/Y)
Total stockholders'
deficit
-$291,000K
(-292.35%↓ Y/Y)
Additional paid-in capital
$4,518,000K
(3.28%↑ Y/Y)
Deferred compensation
obligation
$10,000K
(25.14%↑ Y/Y)
Total liabilities
$1,548,000K
(34.85%↑ Y/Y)
Noncontrolling interest
$7,000K
(0.00%↑ Y/Y)
Liabilities for sales of
future royalties
$1,126,000K
(43.85%↑ Y/Y)
Total current
liabilities
$351,000K
(19.70%↑ Y/Y)
Other liabilities
$41,000K
(135.66%↑ Y/Y)
Deferred tax liabilities
$30,000K
(-0.19%↓ Y/Y)
Accrued liabilities
$221,000K
(22.24%↑ Y/Y)
Liabilities for sales of
future royalties
$76,000K
(19.00%↑ Y/Y)
Accounts payable
$39,000K
(13.90%↑ Y/Y)
Other liabilities
$15,000K
(481.17%↑ Y/Y)
Buy us a coffee